{"id":92858,"date":"2023-07-18T17:29:00","date_gmt":"2023-07-18T15:29:00","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=92858"},"modified":"2023-07-18T14:43:18","modified_gmt":"2023-07-18T12:43:18","slug":"aatec-seed-financing","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/","title":{"rendered":"AATec Medical launches with 2.7 million euros in seed financing"},"content":{"rendered":"
\n

AATec Medical works with the active ingredient alpha-1-antitrypsin (AAT). This human serine protease inhibitor (SERPIN) is responsible for protecting tissue from protease damage, meaning it has both anti-inflammatory and antiviral effects. The startup has found a way to industrially synthesize AAT, which previously could only be produced from human blood plasma. This significantly reduces the price of the active ingredient, opening up new application possibilities. These include administration in combination with an innovative inhalation technology for the treatment of respiratory diseases.<\/p>\n\n\n\n

The company's technology<\/a> is protected by a patent portfolio and is based on research work by co-founders Dr. Manfred Stangl, Head of Kidney and Pancreas Transplantation at the University Hospital of Munich and Chief Scientific Officer of AATec, Dr. Michael Strassmair, Head of the Department of Hand Surgery at the Manus Sana Hospital in Starnberg\/Munich and Chief Medical Officer of AATec.<\/p>\n\n\n\n

AATec plans first clinical trials for 2024<\/h2>\n\n\n\n

With the announcement of the seed financing round, the Startup<\/a> simultaneously enters stealth mode and announces the start of operational activities. The \u20ac2.7 million invested comes from unnamed private investors, industry experts, and family offices. The funds will be used to scale the startup's technology and expand the team. The startup also plans to prepare the clinical development of its first product candidate, ATL-105, an innovative formulation for the inhaled treatment of respiratory diseases, for launch in 2024.<\/p>\n\n\n\n

Dr. R\u00fcdiger Jankowsky<\/strong>, Co-founder and CEO of AATec, said:<\/p>\n\n\n\n

"I am excited by the enormous therapeutic potential of alpha-1 antitrypsin, which has been validated by our preclinical research. Combined with innovative inhalation technology, we will make a decisive difference in the future treatment of inflammatory and infectious diseases. Our lean development approach, implemented by our expert team and supported by renowned academic experts and industry partners, enables an efficient process, allowing us to begin clinical trials in 2024."<\/p><\/blockquote>\n\n\n\n

Dr. Karsten Ottenberg<\/strong>, co-founder of AATec and Chairman of the Advisory Board, added:<\/p>\n\n\n\n

"We are developing AATec Medical with the vision that alpha-1 antitrypsin has the potential for global societal impact. It can address the high unmet medical need for a range of serious diseases, including the challenges posed by today's endemic and potentially pandemic viral diseases. I am very pleased that we have been able to attract an experienced management team, led by CEO R\u00fcdiger Jankowsky, who has extensive experience in managing startup companies and end-to-end biopharmaceutical product development."<\/p><\/blockquote>\n<\/div>","protected":false},"excerpt":{"rendered":"

The biotech startup AATec Medical is working on a novel anti-inflammatory drug for the treatment of respiratory diseases. The Munich-based company has now secured \u20ac2.7 million in its seed financing round.<\/p>","protected":false},"author":33,"featured_media":92859,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5633,1],"tags":[4915,371,52],"acf":[],"yoast_head":"\nAATec Medical startet mit 2,7 Millionen Euro Seed-Finanzierung - Munich Startup<\/title>\n<meta name=\"description\" content=\"Das Biotech-Startup AATec konnte sich 2,7 Millionen Euro f\u00fcr die Entwicklung seines entz\u00fcndungshemmenden Medikaments sichern.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AATec Medical startet mit 2,7 Millionen Euro Seed-Finanzierung - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Das Biotech-Startup AATec konnte sich 2,7 Millionen Euro f\u00fcr die Entwicklung seines entz\u00fcndungshemmenden Medikaments sichern.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-18T15:29:00+00:00\" \/>\n<meta name=\"author\" content=\"Maximilian Feigl\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maximilian Feigl\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/\",\"url\":\"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/\",\"name\":\"AATec Medical startet mit 2,7 Millionen Euro Seed-Finanzierung - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/07\/laboratory-563423_12801.jpg\",\"datePublished\":\"2023-07-18T15:29:00+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509\"},\"description\":\"Das Biotech-Startup AATec konnte sich 2,7 Millionen Euro f\u00fcr die Entwicklung seines entz\u00fcndungshemmenden Medikaments sichern.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/07\/laboratory-563423_12801.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/07\/laboratory-563423_12801.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Aatec\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AATec Medical startet mit 2,7 Millionen Euro Seed-Finanzierung\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509\",\"name\":\"Maximilian Feigl\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g\",\"caption\":\"Maximilian Feigl\"},\"description\":\"Maximilian Feigl berichtet seit 2020 \u00fcber das M\u00fcnchner Startup \u00d6kosystem. Dabei haben es dem studierten Politikwissenschaftler vor allem Deeptech-Themen angetan.\",\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/feigl\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2023\/07\/laboratory-563423_12801.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AATec Medical launches with 2.7 million euros in seed financing - Munich Startup","description":"The biotech startup AATec secured 2.7 million euros for the development of its anti-inflammatory drug.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/","og_locale":"en_US","og_type":"article","og_title":"AATec Medical startet mit 2,7 Millionen Euro Seed-Finanzierung - Munich Startup","og_description":"Das Biotech-Startup AATec konnte sich 2,7 Millionen Euro f\u00fcr die Entwicklung seines entz\u00fcndungshemmenden Medikaments sichern.","og_url":"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2023-07-18T15:29:00+00:00","author":"Maximilian Feigl","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Maximilian Feigl","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/","url":"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/","name":"AATec Medical launches with 2.7 million euros in seed financing - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/07\/laboratory-563423_12801.jpg","datePublished":"2023-07-18T15:29:00+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509"},"description":"The biotech startup AATec secured 2.7 million euros for the development of its anti-inflammatory drug.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/07\/laboratory-563423_12801.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/07\/laboratory-563423_12801.jpg","width":1280,"height":853,"caption":"Aatec"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/en\/92858\/aatec-seed-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"AATec Medical startet mit 2,7 Millionen Euro Seed-Finanzierung"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509","name":"Maximilian Feigl","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g","caption":"Maximilian Feigl"},"description":"Maximilian Feigl has been reporting on the Munich startup ecosystem since 2020. The political scientist is particularly interested in deeptech topics.","url":"https:\/\/cms.munich-startup.net\/en\/author\/feigl\/"}]},"og_image":[{"width":1280,"height":853,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/07\/laboratory-563423_12801.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1689684198:42","_edit_last":"42","_yoast_wpseo_focuskw":"AATec","_yoast_wpseo_metadesc":"Das Biotech-Startup AATec konnte sich 2,7 Millionen Euro f\u00fcr die Entwicklung seines entz\u00fcndungshemmenden Medikaments sichern.","_yoast_wpseo_linkdex":"78","_thumbnail_id":"92859","wbounce_status":"default","_yoast_wpseo_primary_category":"5633","_yoast_wpseo_focuskw_text_input":"","_yoast_wpseo_content_score":"30","ms_image_format":"contentwidth","_ms_image_format":"field_5cb8587572c8b","ms_dachzeile":"","_ms_dachzeile":"field_5cd9b7f365df5","ms_bump_post_date":"","_ms_bump_post_date":"field_5d1341edcf42a","guest_author_name":"","_guest_author_name":"field_5cee78a6016f9","guest_author_image":"","_guest_author_image":"field_5cee7914016fb","guest_author_description":"","_guest_author_description":"field_5cee78dd016fa","ms_post_image_caption":"","_ms_post_image_caption":"field_5f735b0735284","ms_post_image_credit":"","_ms_post_image_credit":"field_5f735b1435285","suppress_startupbox":"0","_suppress_startupbox":"field_60a64b0b6efc6","_yoast_wpseo_estimated-reading-time-minutes":"2","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/92858"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=92858"}],"version-history":[{"count":2,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/92858\/revisions"}],"predecessor-version":[{"id":92862,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/92858\/revisions\/92862"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/92859"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=92858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=92858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=92858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}